Survival Outcomes in Patients with Early and Locally Advanced BRCA1‑Associated Breast Cancer in the Sverdlovsk Region, Russia
Ural Medical Journal · 02.11.2026 · 25 (5) · 70-85
DOI: 10.52420/umj.25.5.70. ↗Kurz gefasst
Fachartikel in der Zeitschrift Ural Medical Journal, online erschienen am 02.11.2026. Verfasst von R. A. Aristov und 6 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Introduction
Breast cancer (BC) remains the leading cause of cancer morbidity among women. Hereditary forms exhibit distinct clinical behaviour and require personalized management. Despite extensive international research, the prognostic significance of BRCA-associated BC remains debated, and Russian data are scarce. The purpose of study is to analyze overall survival (OS) and progression-free survival (PFS) in patients with BRCA-associated BC in the Sverdlovsk region, and to assess these outcomes by molecular subtype. Materials and methods . This retrospective cohort study included 117 patients with stage I–III BC who underwent genetic testing by polymerase chain reaction with subsequent next-generation sequencing verification between 2018 and 2021. Group 1 comprised 53 patients with BRCA1 mutations; group 2 comprised 64 patients without BRCA1/2 mutations. Groups were matched for clinical stage and molecular subtype. Survival was estimated by Kaplan–Meier analysis with log-rank testing; independent prognostic factors were assessed using Cox proportional hazards models.
Results
Five-year OS was 86.8 % in group 1 versus 76.6 % in group 2; seven-year OS was 75.5 % versus 75.0 %. Five-year PFS was 77.0 % versus 65.4 %; seven-year PFS was 74.5 % versus 65.4 %. Differences were not statistically significant. Stage-specific analysis revealed no significant differences. In multivariate Cox analysis, BRCA1 mutation status was not a significant predictor of progression or death. Triple-negative subtype, stage III, and disease progression were significant predictors of death.
Conclusion
BRCA1 mutations do not worsen prognosis in BC and may be associated with more favourable survival. These findings underscore the importance of molecular genetic testing and may inform personalized treatment.
Zitieren
APA
Aristov, R. A., Magdalyanova, M. I., Dorofeev, A. V., Knysh, O. E., Tretyakova, Y. D., Tsaur, G. A., & Popova, A. Y. (2026). Survival Outcomes in Patients with Early and Locally Advanced BRCA1‑Associated Breast Cancer in the Sverdlovsk Region, Russia. Ural Medical Journal, 25(5), 70-85. https://doi.org/10.52420/umj.25.5.70.
Vancouver
Aristov RA, Magdalyanova MI, Dorofeev AV, Knysh OE, Tretyakova YD, Tsaur GA, et al. Survival Outcomes in Patients with Early and Locally Advanced BRCA1‑Associated Breast Cancer in the Sverdlovsk Region, Russia. Ural Medical Journal. 2026;25(5):70-85. doi:10.52420/umj.25.5.70.
BibTeX
@article{Aristov2026,
author = {Aristov, R. A. and Magdalyanova, M. I. and Dorofeev, A. V. and Knysh, O. E. and Tretyakova, Yu. D. and Tsaur, G. A. and Popova, A. Yu.},
title = {Survival Outcomes in Patients with Early and Locally Advanced BRCA1‑Associated Breast Cancer in the Sverdlovsk Region, Russia},
journal = {Ural Medical Journal},
year = {2026},
volume = {25},
number = {5},
pages = {70--85},
doi = {10.52420/umj.25.5.70.}
}
EUVIMED